FDA Advisors Recommend Approval Of Taxol for Node-Positive Breast Cancer
In Brief: Justice Department Files Civil Suit To recover $25 Billion From Tobacco
ODAC Actions: Large Subset analysis Of CALGB Study Was Basis for BMS Taxol Application
UFT – Leucovorin Combo Not A Breakthrough, But could Merit Approval, Committee Says
Roferon A Application Marred By Mission Data, Protocol, Compliance
Underpowered Study Of Evacet Dashes Approval Hopes
NCI Programs: Institute Funds 24 DNA Microarray Centers
Trending Stories
- Trump administration is removing the mainstays of NCI and the federal government’s cancer program
Peer review, registries, and evidence-based patient information take a big hit - NIH eliminates the NCI Board of Scientific Advisors
Over its 28 year history, BSA shaped NCI-funded extramural science - Bhattacharya cancels NIH all-hands meeting
- In the Headlines: “There’s no one to stand up for NCI right now.”
- An opportunity for Trump: Position U.S. cancer science to lead the world
- Cyber-iconoclast Vinay Prasad named head of FDA’s CBER
An oncologist, Prasad has criticized accelerated approval, next-gen sequencing, and targeted therapies